Compare GSK plc (GSK) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wynn Resorts, Limited — how do they compare? GSK plc trades at $52.68 (market cap $101.34B), while Wynn Resorts, Limited trades at $98.87 (market cap $10.07B). The key difference: GSK plc is far larger — about 10.1× Wynn Resorts, Limited's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | WYNN | |
|---|---|---|
Market Cap | $101.34B | $10.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $133.34 |
52-Week Low | $36.20 | $94.78 |
Enterprise Value | $121.95B | $20.44B |
Dividend Yield | 3.49% | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Wynn Resorts (WYNN) trades at $95.9, down 1.27% over 24 hours, with a bearish technical signal and recent earnings misses. The company reported Q1 2026 EPS of $1.25, meeting expectations but missing in prior quarters, while revenue growth remains steady at $7.14B in 2025. High debt levels and negative shareholder equity pose fundamental concerns, though analyst sentiment is bullish with a $135 consensus price target.
The stock offers upside potential based on analyst targets but faces headwinds from margin pressure, geopolitical risks in expansion projects, and volatile casino demand. Investment appeal hinges on execution in Macau and Las Vegas, with cash flow stability needed to address leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
